Navigation Links
PRA International Expert to Speak at China Drug Safety Summit
Date:11/16/2010

RALEIGH, N.C., Nov. 16, 2010 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces that the head of our Safety and Risk Management (SRM) group will speak at the 3rd annual China Drug Safety and Public Policy Summit being held in Shanghai 18-19 November 2010.

Dr. Sabine Richter, PRA's Vice President of SRM, will deliver the opening day's keynote address, "Challenges of Drug Safety in Global Clinical Trials." Her presentation will address the challenges and opportunities associated with handling safety data from global studies, including those in Asian countries. She will also review how cultural and regulatory factors affect the collection, reporting, and regulatory acceptance of safety data from trials performed outside of the United States and Europe.

Dr. Richter has over 20 years of research experience in the pharmaceutical and CRO industries, as well as in academia. Since joining PRA's SRM team in 2004, she has delivered numerous projects for a variety of clients and led large, long-term safety programs involving as many as 50 countries on five continents.  

PRA's SRM group has more than 110 experts providing safety and risk management services throughout the entire product life cycle. Most SRM staff members are healthcare professionals (nurses, pharmacists, physicians) or life scientists. They offer consultancy as well as routine and specialty pharmacovigilance services. Our drug safety centers are based in Mannheim, Germany; Charlottesville, VA (US); and Sao Paulo, Brazil.

For more information about the conference, please visit www.prainternational.com and click on "Events."



About PRA International

PRA International conducts clinical trials in more than 85 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas, with specialization in Oncology, Neurosciences, Respiratory/Allergy, Cardiovascular and Infectious Diseases. In the last five years, PRA has supported over 3000 clinical trials through its 38 global offices.

PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.

To learn more about PRA International, please visit www.PRAinternational.com, email Endpoints@PRAintl.com or call our Global Headquarters at +1 (919) 786-8200.


'/>"/>
SOURCE PRA International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
2. Yongye Biotechnology International Retains CCG Investor Relations
3. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
4. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
5. Yongye Biotechnology International Announces Second Quarter Results
6. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
7. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
8. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
9. Mindray Medical International Announces Second Quarter 2008 Results
10. Singapore to hold international pow-wow
11. Sangui BioTech International, Inc. Files Remaining Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017   Sienna Biopharmaceuticals, Inc. ... company, today announced that Richard Peterson will ... 24.   Peterson, who brings more than two ... Smither , who is retiring at the end of ... advisory capacity. Peterson joins Sienna from Novan, Inc., where ...
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics ... DCVax® personalized immune therapies for solid tumor cancers, ... $7.5 million financing it announced last Friday, March ... to several institutional investors securities totaling 28,843,692 shares, ... share, and 10,000,000 shares of Class C Warrants ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
(Date:3/23/2017)... ... 23, 2017 , ... Advanced Polymer Monitoring Technologies (APMT), a ... “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd will lead ... Floyd’s career has spanned 30 years in the chemicals and equipment industries. Sig ...
Breaking Biology Technology:
(Date:3/7/2017)... , March 7, 2017   HireVue , the ... global companies identify the best talent, faster, today announced ... Sales Officer (CSO) and Diana Kucer as ... out a seasoned executive team poised to drive continued growth ... on a year of record bookings in 2017. ...
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant ... At PTE ... March, Materna will present its complete end-to-end passenger journey, ... real benefit for passengers. To accelerate the whole passenger handling ... solutions to take passengers through the complete integrated process with ...
Breaking Biology News(10 mins):